Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pfizer to Develop Market for Sutent as First-Line Therapy for RCC
July 28, 2008
- Clopidogrel May Be Less Effective in Japanese than in Westerners
July 28, 2008
- Eisai Develops Add'l Indications, Dosage Forms for Aricept as Part of Life Cycle Management
July 28, 2008
- Korosho Presents Draft Vision for Medical Devices Industry
July 28, 2008
- Kyowa Hakko, Lonza Extend Their Strategic Collaboration
July 28, 2008
- Use of Tamiflu Not Correlated with Abnormal Behavior: Korosho Working Group
July 21, 2008
- Chuikyo to Conduct Survey to Verify Effects of FY2008 Medical Fee Revision
July 21, 2008
- Switch OTC Drugs Hold Key to Market Revitalization
July 21, 2008
- FPAMJ's Proposal Meets Harsh Opposition at Chuikyo
July 21, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 21, 2008
- Industry Needs to Present More Data on Reform Proposed by It
July 21, 2008
- Korosho's Draft Report Sits on the Fence Re Qualification of Store Managers
July 21, 2008
- NEW PRODUCTS／Daiichi Sankyo, Lead Chemical: Loxonin Tape
July 21, 2008
- New OTC Drug Sales System Ready to Go
July 21, 2008
- BUSINESS NEWS IN BRIEF
July 21, 2008
- GENERICS NEWS IN BRIEF
July 21, 2008
- Takeda Applies for Mutual Agreement Procedure to Resolve Double Taxation
July 21, 2008
- OHARA Aims at Sales of \700 Mil. with Amlodipine Generics in FY2009
July 21, 2008
- Ain Pharmaciez to Achieve 90% Price Agreement Rate by End of July
July 21, 2008
- Korosho Tests Purity of Generics of 10 APIs
July 21, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…